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The oestrogen-like effect of 4-hydroxytamoxifen on
induction of transforming growth factor alpha mRNA in
MDA-MB-231 breast cancer cells stably expressing the
oestrogen receptor
AS Levenson, DA Tonetti and VC Jordan
Robert H Lurie Cancer Centre, Northwestern University Medical School, 303 E. Chicago Avenue, Chicago, IL 60611, USA
Summary Oestrogens and antioestrogens modulate the synthesis of transforming growth factor alpha (TGF-a) in breast cancer cells. The
purpose of the present report was to examine regulation of TGF-a gene expression by oestradiol (E2) and antioestrogens in MDA-MB-231
breast cancer cells transfected with either the wild-type or mutant oestrogen receptor (ER). We recently reported the concentration-
dependent E2 stimulation of TGF-a mRNA in MDA-MB-231 ER transfectants (Levenson et al, 1997). We now reportthat4-hydroxytamoxifen
(4-OHT) shows oestrogen-like effects on the induction of TGF-a gene expression in our transfectants. Accumulation of TGF-a mRNA in
response to both E2 and 4-OHT but not in response to the pure antioestrogen ICI 182,780 suggests that E2-ER and 4-OHT-ER complexes
can bind to an oestrogen response element (ERE), located in the promoter region of the TGF-a gene and can activate transcription of the
gene. Surprisingly, no activation of luciferase expression was observed after transient transfection of the TGF-a ERE/luciferase reporter
constructs. Possible activation of an alternative ER-mediated pathway responsible for the regulation of TGF-a gene expression in the ER
transfectants is discussed.
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One of the most fascinating aspects of the pharmacology of the
non-steroidal antioestrogen tamoxifen is the target site-specific
effects. Tamoxifen is the endocrine therapy ofchoice for all stages
of breast cancer (Jordan, 1996) and it is the only agent able to
reduce the incidence of contralateral breast cancer (Early Breast
Cancer Trialists' Collaborative Group, 1992). Anti-tumour effect
of tamoxifen in breast depend on its antioestrogenic activity; an
effect verified in laboratory tests (Furr and Jordan, 1984). On the
other hand, tamoxifen acts as an oestrogen to cause the growth of
endometrial cancers (Gottardis et al, 1988), to maintain bone
density in rats (Jordan et al, 1987) and humans (Love et al, 1992)
and to lower circulating cholesterol (Love et al, 1991). Indeed,
identification of target site-specific effects of tamoxifen has
prompted the pharmaceutical industry to develop new targeted
antioestrogens (selective oestrogen receptor (ER) modulators) to
treat osteoporosis and coronary heart diseases (Tonetti andJordan,
1996a and b). Although several hypotheses have been advanced to
explain the target site-specific effects of non-steroidal antioestro-
gens (Halachmi et al, 1994; Yang et al, 1996) and the development
of tamoxifen-resistant breast tumours (Tonetti and Jordan, 1995),
there is, as yet, no unifying theory to explain the action of the
drugs at the subcellular level. This, in part, is because there is a
paucity ofexperimental model systems for breast cancer in which
antioestrogens and oestrogens exhibit equivalent actions.
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Recently we developed stable transfectants of MDA-MB-231
ER-negative breast cancer cells with the cDNA ofwild-type (S30
cells) and codon 351asp-tyr mutant ER (BC-2 cells) (Jiang and
Jordan, 1992; Catherino et al, 1995). The naturally occurring
codon 351asp-tyr point mutation in the ligand-binding domain
(LBD) ofER was identified in a tamoxifen-stimulated tumour line
developed from MCF-7 breast cancer cells implanted into athymic
nude mice (Wolf and Jordan, 1994a and b). Our initial goal was
to reassert hormonal control over hormone-independent breast
cancer cells by transfecting the hER gene into cells lacking this
protein (Jiang and Jordan, 1992). During our investigation of the
growth control mechanisms in the S30 cell line, we discoveredthat
oestrogen causes an increase in the mRNA oftransforming growth
factor alpha (TGF-a) (Jeng et al, 1994). The product can be easily
measured by Northern blotting because the basal signal is already
dramatically amplified in MDA-MB-231 cells.
The aim ofthis paper is to report progress in new investigations
of TGF-a gene regulation by 17p-oestradiol (E2) and antioestro-
gens in S30 cells (wild-type ER) (Jiang and Jordan, 1992) and in
BC-2 cells (codon 351asp-tyr mutant ER) (Catherino et al, 1995).
Both S30 and BC-2 transfectants exhibit an E2 concentration-
dependent induction ofTGF-a mRNA expression (Levenson et al,
1997). After an initial examination of the effects of keoxifene
(raloxifene) on TGF-a mRNA in our transfectants when ralox-
ifene exhibits oestrogen-like effects with mutant ER (BC-2 cells)
but not with wild-type ER (S30 cells) (Levenson et al, 1997), we
were surprised to find that the potent tamoxifen metabolite 4-
hydroxytamoxifen (4-OHT) (Jordan et al, 1977) produced an
increase in TGF-a mRNA levels in a concentration-dependent
manner in both cell lines. Thus both an oestrogen- and an anti-
oestrogen-ER complex produce the same response at the same
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Figure 1 The plasmid map of the TGF-a ERE-luciferase plasmid constructs
used in transient transfection experiments
gene. The pure antioestrogen ICI 182,780 (Wakeling et al, 1991),
in contrast, can block the induction of TGF-x expression by E2
and 4-OHT in both cell lines. The observation that TGF-a mRNA
is induced in response to both E2 and 4-OHT in both cell lines
provides us with a powerful and unique model system in which to
investigate the mechanism of how both E2 and 4-OHT can acti-
vate the same gene. As a first step in dissecting the signal trans-
duction pathway ofgene regulation, we took the direct approach of
studying gene activation by E2 and 4-OHT through putative
oestrogen response elements (EREs) located in the promoter
region of the TGF-a gene (Saeki et al, 1991). Unlike the
consensus ERE, the putative EREs in the TGF-a promoter region
were unable to activate a luciferase reporter gene in response to E2
or 4-OHT. These data suggest that an alternative, more complex
mechanism mustbe available forligands to initiate transcription of
the TGF-ax gene.
MATERIALS AND METHODS
Cell culture
The MDA-MB-231 cell line used was originally obtained from
American Type Culture Collection (Rockville, MD, USA), and the
clonal cell line (clone 1OA) was used for transfection of either
wild-type ER cDNA (HEGO, S30 cells) (Jiang and Jordan, 1992)
or codon 351asptyr mutant ER cDNA (HETO, BC-2 cells)
(Catherino et al, 1995). Cells were maintained in phenol red-free
minimal essential medium (MEM) containing 5% charcoal-
stripped calf serum, penicillin (100 U ml-1), streptomycin
(100 ,ug ml-), L-glutamine (2 mM), G-418 (500 ,ug ml-'), bovine
insulin (6 ng ml-') and non-essential amino acids (100 mM). All
materials were obtained from Gibco BRL, Life Technologies
(Gaithersburg, MD, USA). Oestradiol was purchased from Sigma
Chemical (St Louis, MO, USA), 4-OHT was a generous gift from
Zeneca Pharmaceuticals (Macclesfield, UK) and ICI 182,780 was
a generous gift from Dr Alan Wakeling (Zeneca Pharmaceuticals).
All compounds were dissolved in 100% ethanol and added to the
media in 1:1000 dilution for a final ethanol concentration no
greater than 0.2%.
Northern blot analysis
Northern blot analysis was performed essentially as described
previously (Levenson et al, 1997). Briefly, total RNA was isolated
from cells after a 24-h treatment with compounds. Twenty micro-
grams of RNA sample was fractionated in a 1.2% agarose-
formaldehyde gel and transferred to a nylon membrane
(Hybond-N+; Amersham, Arlington Heights, IL, USA). The
membranes were hybridized at 42'C with 32P-labelled TGF-at
probe (plasmid generously provided by Dr Rik Derynck,
Genetech, CA, USA). The membranes were then washed and
autoradiographed by exposure to Hyperfilm (Amersham) at-80°C
with intensifying screens for 1-2 days. The expected 4.8-kb tran-
script was detected in both cell lines. Subsequently, the blots were
stripped and reprobed with ,-actin cDNA. The signals were
quantitated by phosphorimage analysis (Molecular Dynamics
phosphorimager, Image Quant software).
Semiquantitative reverse transcriptase-polymerase
chain reaction (RT-PCR)
One microgram of total RNA isolated from cells as described
above was used in a reverse transcription reaction to obtain cDNA
using the SuperScript Preamplification System for First Strand
cDNA synthesis kit (Gibco BRL).
Oligonucleotide primers were synthesized using published
cDNA sequences for TGF-o (Tahara et al, 1995) and P2-
microglobulin (P2-M) (Noonan et al, 1990). The primers used in
the PCR reactions are as follows:
Gene Primer sequences
TGF-a 5'-ATGGTCCCCTCGGCTGGACA
5'-CTGCAGGTTCCATGGAAGCA
P2-M 5-ACCCCCACTGAAAAAGATGA
5'-ATCTTCAAACCTCCATGATG
Sizes ofthe
amplified
product (bp)
182
120
The PCR mixture consisted of the two primers (15giM),
deoxynucleotidetriphosphates (200jiM), template cDNA, lOx
buffer (Perkin Elmer), 1.0 unit of AmpliTaq DNA polymerase
(Perkin Elmer), 1.5 mM magnesium chloride in a total volume of
25 gl. The optimal number ofamplification cycles was determined
for each PCR product to avoid the plateau phase. Twenty-five PCR
cycles were found to be optimal for both gene products. Cycling
was performed with a thermal cycler (Gene Amp PCR System
9600, Perkin Elmer) according to the following parameters: denat-
uration at 94°C for 30 s, annealing at 55°C for 15 s, extension at
72°C for 30 s, followed by afinal incubation at72'C for5 min. The
PCR products were subjected to 8% polyacrylamide gel
electrophoresis. The amplified products were visualized by staining
with ethidium bromide. When hot PCR was performed, the gel was
dried and then exposed to radiographic film for several hours. The
signals were quantified by scanning densitometry of the auto-
radiograms, and TGF-a was normalized against theP2-M signal.
Western blot analysis
Whole-cell extracts were prepared from cells treated for 24 h with
compounds by lysis of cold phosphate-buffered saline (PBS)-
washed cells in lysis buffer (NP40-1%, 20 mM Tris-HCl, 150 mM
sodium chloride. The protein concentration was measured using
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Figure 2 Concentration-dependent induction of TGF-a mRNA expression in
S30 cells (A) and BC-2 cells (B) treated with 4-OHT. Total RNA was isolated
24 h after treatment as described in Materials and methods. The Northern
blots show the TGF-a 4.8-kb message and the corresponding ,B-actin signal.
The bar graph shows the inducible [the ratio of normalized TGF-a mRNA
levels in cells treated with 4-OHT to the normalized TGF-a mRNA levels in
untreated cells (control)] levels as determined by densitometric analyses
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Figure 3 Induction of TGF-a mRNA expression in MCF-7, MDA-MB-231
and S30 cell lines analysed by semiquantitative RT-PCR as described in
Materials and methods. The figure shows the TGF-a signal (182 bp) and the
corresponding P2-M (120 bp) used as an internal control. The sources for
RNAs were the following: control, cells treated with EtCH vehicle; E2, cells
treated with 10Q-9 m oestradiol; 4-OHT, cells treated with 1Q-7 m 4-
hydroxytamoxifen
the Bio-Rad Protein Assay kit (Bio-Rad Laboratories, CA, USA)
with bovine gamma globulin as a standard. Equal amounts of
protein were subjected to an 8% polyacrylamide gel with a 5%
stacking gel. After electrophoresis, proteins were transferred to
Hybond, enhanced chemiluminescence (ECL) nitro-cellulose
membrane (Amersham, Arlington Heights, IL, USA) using a Mini
Trans-Blot Electrophoretic Transfer Cell (Bio-Rad Laboratories).
Loading equivalence and transfer efficiency were monitored by
Coomassie blue staining of the gel. The membrane was blocked
overnight in blocking solution containing PBS-Tween and 7% dry
milk. The membrane was then incubated with a 1:500 dilution ofthe
anti-ER antibody H222 in PBS-Tween with 10% calfserumfor2 hat
room temperature. The H222 antibody was a generous gift from
Abbott Laboratories (Abbott Park, IL, USA). After several washing
cycles, horseradish peroxidase-conjugated goat anti-ratIgG antibody
(1:2500 dilution) was added to the membrane and incubated for
another 2 h at room temperature. The ECL Western blot detection
reagents (Amersham, Buckinghamshire, UK) were used for visual-
ization. The ECL detected blots were exposed to autoradiography
film (Hyperfilm-ECL) for 1-5 min at room temperature.
Reporter gene constructs
The reporter construct pERE-Luc contains one Xenopus laevis
vitellogenin A2 ERE (singlet ERE-luciferase), as has been
described previously (Catherino and Jordan, 1995).
We used the samepT109 luciferase plasmid (Nordeen, 1988) for
constructs containing the putative TGF-a EREs. Oligonucleotides
TGF-xl, TGF-a2, and TGF-adoublet (Figure 1), corresponding to
the putative TGF-a EREs previously reported by Saeki et al
(1991), were synthesized to contain HindIII sites at each end. The
oligonucleotides were annealed, phosphorylated and ligated into
the Hindlll site of the pT109 luciferase plasmid (Nordeen, 1988)
and transformed to E. coli DH5a cells. Individual colonies were
chosen for plasmid preparation and restriction digestion to verify
the presence of an insert. Plasmids containing inserts were
sequenced to verify the correct sequence, orientation and to ensure
the insertion of single and not multiple EREs. Two independent
luciferase constructs were prepared foreachTGF-al, TGF-a2 and
TGF-odoublet EREs.
The plasmid pCMVP (Clonetech, Palo Alto, CA, USA), which
contains the P-galactosidase gene, was used as an internal control
for transient transfection efficiency in all experiments.
Transient transfection and luciferase assay
MCF-7 and BC-2 cells were seeded in six-well plates at 5 x 105
cells per well in phenol red-free MEM media containing 5% char-
coal-stripped calf serum as described above. Twenty-four hours
(MCF-7) or 48 h (BC-2) later, the MCF-7 cells were transiently
transfected using the calcium phosphate method (Catherino and
Jordan, 1995), and the BC-2 cells using a liposome method
(Campbell, 1995). Each well of cells was co-transfected with
1.0 ,ug of the reporter-luciferase construct along with 0.5 jg of the
pCMV-3-gal plasmid to normalize the transfection efficiency. After
4-6 h, the transfection mixture was removed and media containing
compound(s) was added. As an intra-assay standard, a vitellogenin
singlet ERE/luciferase reporter construct was transfected in parallel
to serve as a comparison to each TGF-a-luciferase plasmid.
Luciferase activity was measured 18-24 h later using a Monolight
2010 luminometer (Analytical Luminescence Laboratory), and 1-
gal activity was assayed as in Luyten et al (1988). Total luciferase
units were divided by the total 1-gal units and expressed as a fold
increase over the control (untreated = 1). The mean± s.e. ofat least
three independent experiments performed in triplicate was graphed
as a percentage of the maximum activity achieved with the vitel-
logenin ERE/luciferase construct.
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Figure 4 Concentration-dependent induction of TGF-a mRNA expression
by E2 and 4-OHT in S30 cells. Total RNA was isolated 24 h after treatment
with compounds as described in Materials and methods. The Northern blot
shows the TGF-a 4.8-kb message and the corresponding ,-actin signal. The
graph shows inducible levels of TGF-a mRNA [ratio of normalized TGF-a
mRNA in cells treated with compounds to normalized levels in untreated cells
(control)] as determined by densitometric analyses
RESULTS
Concentration-dependent induction of TGF-a mRNA by
4-OHT in S30 and BC-2 cell lines
We have previously demonstrated that there is a concentration-
dependent induction of TGF-a mRNA by E2 in S30 (wild-type
ER) and BC-2 (mutant ER) cells (Levenson et al, 1997). We now
examine the action of4-OHT on the expression ofthe TGF-ax gene
in these transfectants. The effect of 4-OHT on the expression of
TGF-a mRNA in S30 and BC-2 cells was determined by Northern
blot analyses 24 h after the addition ofvarious concentrations of4-
OHT (Figure 2). Figure 2A shows that 4-OHT stimulates accumu-
lation ofTGF-a mRNA in S30 cells in a concentration-dependent
manner. This agonist activity of the drug was unexpected because
we and others had previously linked changes in the pharmacolog-
ical properties of non-steroidal antioestrogens with mutations of
the ER (Mahfoudi et al, 1995; Montano et al, 1996; Levenson et al,
1997). Similar to the effect of4-OHT seen in S30 cells (wild-type
ER), there was a concentration-dependent induction of TGF-a
mRNA in BC-2 cells, expressing mutant ER (Figure 2B). These
results suggest that mechanisms other than mutation ofthe ER are
responsible for the agonistic effect of 4-OHT on TGF-ax expres-
sion in these transfectants. Interestingly, the relative amount of
TGF-a mRNA induced in BC-2 cells was more than twice that
induced in the S30 (Figure 2).
Our attempt to detect TGF-a mRNA in MCF-7 cells using total
RNA in Northern blot were not successful because of the low
abundance of transcripts. To illustrate the differences in the cell
lines, we used semiquantitative RT-PCR to compare the effect of
E2 and 4-OHT on TGF-ax mRNA expression in MCF-7, MDA-
MB-231 and S-30 cells (Figure 3). Our results show that (1) in
MCF-7 cells TGF-a mRNA levels were increased by E2 (fivefold)
but not by 4-OHT; (2) in MDA-MB-231 cells TGF-ax mRNA
levels were unaffected by E2 treatment and were modestly
reduced by 4-OHT; and (3) in S30 cells TGF-axmRNA levels were
increased by both E2 and4-OHT by 9.5- andfourfold respectively.
Although these data should be viewed as semiquantitative only,
they do illustrate the differences in relative amounts of TGF-ac
mRNA expression in different cell lines in response to E2 and 4-
OHT. There is an apparent overexpression of TGF-a mRNA in
response to both E2 and 4-OHT in S30 cells.
Regulation by oestradiol and antioestrogen
As both E2 and4-OHT were able to stimulate TGF-a mRNA in S-
30 and BC-2 cells, we decided to compare the potency of these
two ligands. We performed Northern blot analyses of TGF-x
mRNA expression using total RNAs from S30 cells treated with
various concentrations ofboth compounds on the same membrane
(Figure 4). Both ligands had the same effect on TGF-ca mRNA
levels at concentrations differing by three orders of magnitude
(I0-9M for E2 and I06M for4-OHT), indicating that E2 was more
potent. Although 4-OHT acted as an agonist on TGF-a mRNA
expression when added to cells alone, the possibility existed that
4-OHT and E2 would compete with each other for the ER to
abolish TGF-a induction. However, the combined treatment of
cells with E2 and 4-OHT did not alter TGF-a mRNA induction in
either S30 or BC-2 cell lines, whereas the pure antioestrogen ICI
182,780 completely inhibited the action of E2 in both cell lines
(data not shown).
Pure antioestrogen ICI 182,780 remains a complete
antioestrogen and is able to block E2 and 4-OHT
effects on TGF-a mRNA induction
The intriguing observation that the partial antioestrogen 4-OHT
acts as a complete agonist in this model system prompted us to
study the effect ofother antioestrogens. We have recently reported
the antagonistic action of raloxifene on TGF-ax mRNA induction
in S30 (wild-type ER) cells compared with BC-2 cells expressing
the mutant ER (Levenson et al, 1997). Here, we expand our inves-
tigation and show that in S30 cells raloxifene blocked not only E2
action on the induction of TGF-a mRNA but also 4-OHT action
(Figure SA). Pure antioestrogen ICI 182,780 blocked the action of
E2 and 4-OHT in both cell lines as well as the agonistic action of
raloxifene in BC-2 cells (Figure SB and C).
It is not clear whether stable integration of the transfected ER
gene into chromosomal DNA might affect and alter the regulation
ofER protein expression by E2 and antioestrogens (Levenson and
Jordan, 1994). The mechanism of action for pure antioestrogens
(Wakeling and Bowler, 1988) is believed to result from the
combined ability to reduce steady-state levels of the ER by
increasing the turnover ofthe protein (Gibson et al, 1991; Dauvois
et al, 1992) and to inhibit nucleocytoplasmic shuttling of the
receptor by blocking its nuclear uptake (Dauvois et al, 1993).
Therefore, it was ofinterest to examine the regulation ofexpres-
sion ofthe ER protein by E2 and antioestrogens in ER-transfected
cells. Western blot analyses of whole-cell extracts from S30 and
BC-2 cells treated with compound(s) for24 h revealed an expected
66-kDa ER (Figure 6). As seen in Figure 6A and B levels of ER
protein were slightly down-regulated by E2, up-regulated by 4-
OHT, not much altered by raloxifene and significantly decreased
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Figure 5 Antagonistic effect of raloxifene on induction of TGF-a mRNA by
E2 and 4-OHT in S30 cells (A) and effects of E2 and antioestrogens, or
combinations of compounds on TGF-a mRNA in S30 (B) and BC-2 (C) cells
analysed by Northern blot as described in Materials and methods. Cells were
treated with compound(s) for 24 h. The sources for RNAs were the following:
control, cells treated with EtOH vehicle; E2, cells treated with 10-9 M (A and
B) or 10-8 M (C) oestradiol; 4-OHT, cells treated with 10-7 M 4-
hydroxytamoxifen; Ral, cells treated with 1 0-7 M raloxifene; ICI, cells treated
with 10-6 M ICI 182,780. The above-mentioned concentrations for each
compound were used alone and in combination experiments. f-Actin was
used as a loading control
by ICI 182,780 in both cell lines. Pure antioestrogen ICI 182,780
was able to reduce the amount ofER protein in combination exper-
iments, with the exception of raloxifene in BC-2 cells. It appears
that regulation ofthe steady-state level of the ER protein in trans-
fectants by oestrogen and antioestrogens, in general, is under the
same control mechanisms as the steady-state level of endogenous
ER in MCF-7 cells (Pink and Jordan, 1996).
Both E2 and 4-OHT do not activate the putative TGF-a
EREs in a luciferase reporter plasmid
Although E2 can increase the expression of TGF-a mRNA and
can stimulate the production of TGF-x protein in breast cancer
cells (Lippman et al, 1976; Salomon et al, 1989a and b) and E2-
induced expression of TGF-a can be blocked by antioestrogens
(Murphy and Dotzlaw, 1989), it is not clear whether these effects
of oestrogen are direct or indirect on stimulating transcription of
the TGF-a gene. It has been suggested that two potential imperfect
palindromic ERE-like sequences are present within the human
TGF-a 5'-flanking sequence (Saeki et al, 1991).
To investigate the mechanism of how E2 and 4-OHT can both
activate the same gene we performed transient transfection experi-
ments of luciferase reporter constructs containing each of the
TGF-ax EREs separately, and in combination, retaining the 22-bp
intervening sequence naturally found in the TGF-a promoter
Figure 6 Ligand-induced regulation of the 66-kDa exogenous ER proteins
in S30 (A) and BC-2 (B) cells analysed by Western blot as described in
Materials and methods. Cells were treated with compound(s) for 24 h. Equal
amounts of total protein were run in each lane. The blot was probed with the
antibody H222. The sources for proteins were the following: control, cells
treated with EtOH vehicle; E2, cells treated with 10-9 M (A) or 10 8 M (B)
oestradiol; 4-OHT, cells treated with 1U7 M 4-hydroxytamoxifen; Ral, cells
treated with 10-7 M raloxifene; ICI, cells treated with 106 M ICI 182,780. The
above-mentioned concentrations for each compound were used alone and in
combination experiments
(Figure 1). Initially, we used the MCF-7 cell line and then
confirmed our observations using our transfectants. Figure 7A
shows the results of transient transfection of these constructs into
MCF-7 cells. There was no luciferase activity when cells were
transfected with any of the 'TGF-aERE' constructs. Within the
same assay a vitellogenin singlet ERE/luciferase reporter construct
was used as a standard and was found to be activated by E2.
Similar results were obtained in the T47D breast cancer cell line
(data not shown). Figure 7B shows the results oftransient transfec-
tion experiments of BC-2 cells, which are more easily trans-
fectable than S30 cells. These results show that there is no
activation of 'TGF-a EREs' by E2 at any concentrations and in
fact there was only a very low activation ofthe singlet vitellogenin
ERE construct. These data demonstrate that the putative TGF-a
EREs in the promoter region are very weak and not sufficient
alone to mediate either the E2 or the 4-OHT (data not shown)
signal using our standardized reporter gene construct with a
thymidine kinase (Tk) promoter.
DISCUSSION
Oestrogens are known to regulate the production ofgrowth factors
and their receptors in breast cancer (Lippman and Dickson, 1989).
It is well known that TGF-x mRNA and protein is induced by
oestrogens in responsive breast cancer cells (Bates et al, 1988;
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Figure 7 The relative luciferase activity (normalized to ,-gal activity) of transiently transfected MCF-7 cells (A) and BC-2 cells (B) treated with a range of E2
concentrations. As an intra-assay standard, a vitellogenin singlet ERE/luciferase reporter construct was transfected in parallel to serve as a comparison to each
TGF-a-luciferase plasmid. The results are expressed relative to the luciferase activities for the maximum fold-increase (over the untreated control) that was
achieved with the vitellogenin ERE/luciferase construct for each experiment. The maximum fold-increase for the vitellogenin singlet differed between MCF-7
(50-fold) and BC-2 (threefold) and was assigned an arbitrary value of 100% for each cell line. The mean ± s.e.m. of at least three independent experiments
performed in triplicate was graphed. -{-, Vitellogenin; -o-, TGF-a EREs
Dickson et al, 1992). The fact that this induction is mediated
through the ER was supported by experiments with antioestro-
gens, which were able to block the induction caused by oestrogen
(Murphy and Dotzlaw, 1989; Noguchi et al, 1993). The mecha-
nism of induction of TGF-a in cells is presumed to be direct, via
the classical pathway in which the receptor binds to EREs in the
promoter region ofthe gene as reported by Saeki et al (1991).
In this report, we present the novel observation that endogenous
TGF-a gene expression is stimulated by both E2 and 4-OHT in
ER-negative breast cancer cells, stably transfected with either the
wild-type (S30 cells) or the mutant ER (BC-2 cells). Thus both
oestrogen- and antioestrogen-ER complexes produced the same
response at the same gene in ER transfectants. These results were
unexpected and suprising for two reasons: (1) tamoxifen is an
antioestrogen in breast cancer cells with endogenous ER (MCF-7
cells, Figure 3), whereas it acts as an agonist in ER transfectants;
(2) this agonistic activity of the drug was predictable with the
mutant receptor but not with wild-type ER. Indeed, we have
recently reported the antagonistic action of raloxifene on TGF-at
mRNA induction in S30 (wild-type ER) cells compared with BC-
2 cells (mutant ER) (Levenson et al, 1997). We expanded our
observation with raloxifene in this report and showed that ralox-
ifene acted as an antagonist with wild-type ER and was able to
block the effects of both E2 and 4-OHT in S30 cells (Figure SA).
The pure antiestrogen ICI 182,780 was able to block agonistic
activities of E2 and 4-OHT in S30 cells and agonistic activities of
all three ligands in BC-2 cells, remaining a complete antagonist
with both wild-type and mutant ER (Figure SB and C). The expla-
nation for the selective agonist/antagonist activity of partial
antioestrogens in our model system is currently unclear. However,
it is well known that the ligand-induced alterations in the confor-
mation ofthe ER might be sensed by cellular factors (co-activators
or/and co-repressors) that can mediate the activation functions of
ER (Halachmi et al, 1994; Smith et al, 1997). We think that identi-
fication of such accessory proteins may play a critical role in
dissecting the signal transduction pathway in ER transfectants.
The observation that both wild-type and mutant ER did mediate
the activation ofthe TGF-a gene in a similar manner suggests that
the mutation in the LBD of the receptor does not affect the activa-
tion pathway qualitatively, although we noted quantitative differ-
ences (Figure 2). The ER level in both cell lines is quite high
(BC-2 cells express a higher level of ER than S30) but similar to
that in MCF-7 cells (Catherino et al, 1995). We assume that in
addition to the differences between transcription factor pools that
interact with the ER in MCF-7 cells compared with parental
MDA-MB-231, the different levels ofER in these cell lines might
be responsible for the more intense induction of TGF-a in BC-2
cells compared with S30 cells (see Figure 2).
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We were not able to detect an E2-stimulated response of
luciferase activity after transient transfections of the TGF-at
ERE/luciferase reporter constructs. There are several explanations
that may account for the inability to detect E2-stimulated
luciferase expression in our MCF-7 cells. It is known that MCF-7
sublines differ in their degrees ofresponsiveness to E2 because of
different levels ofendogenous ER protein (Butler et al, 1986). By
manipulating the levels of ER one might be able to get a different
response to E2. Recent databy El-Ashry et al (1996) demonstrated
a 30-fold induction of chloramphenicol acetyltransferase (CAT)
activity by oestrogen in MCF-7 cells supertransfected with a
mouse ER expression vector and the putative TGF-a EREs cloned
within the heterologous mouse mammary tumour virus (MMTV)
promoter. However, in the absence of the exogenous mouse ER,
oestrogen was not able to induce significant and reliable levels of
CAT activity in MCF-7 cells, neither with its own TGF-a
promoter nor with the TGF-x EREs cloned within the MMTV
promoter (EI-Ashry et al, 1996). Similarly, in our experiments
with a reporter plasmid containing the entire promoter region of
the TGF-a gene (pTGF-a-2813Luc, generously provided by Dr D
Salomon, NIH, Bethesda, MD, USA), we did not observe induc-
tion of luciferase activity in oestrogen-treated MCF-7 cells. We
did, however, detect very weaktranscriptional activation with both
E2 and 4-OHT in BC-2 cells, although the results were variable
and inconsistent (data not shown). Thus, our results are in agree-
ment with those ofEl-Ashry et al (1996) in terms ofthe inability of
the TGF-a promoter and TGF-a EREs to mediate a significant
response in MCF-7 cells not boosted with exogenous ER. The
discrepancy between ourresults and those ofEl-Ashry et al (1996)
might be due to differences in the transfected cell lines used (they
used MCF-7 and Cos-7 cells transfected with mouse ER, whereas
we used a different subline of MCF-7 cells not transfected with
exogenous ER and MDA-MB-231 transfected with human ER),
and/or in the nature ofheterologous promoter used in the reporter
constructs (they used MMTV, whereas we used Tk). Finally,
consistent with our results, Saeki et al (1991) reported that a frag-
ment thatjust contained the putative ERE-like elements (pTGF-at-
37OLuc) was very weak and that additional cis-acting elements
might be involved in amplifying the effects ofE2 in MCF-7 cells.
Both E2 and 4-OHT failed to activate putative TGF-a EREs in
MCF-7 and BC-2 cells, suggesting that a pathway other than the
classical ERE pathway may be contributing to the induction ofthe
TGF-a gene in these cells. Activation of the activating protein-I
(AP-1) mediated pathway by the ER-ligand complex has been
reported as an alternative pathway for ER action in breast cancer
cells after long-term tamoxifen treatment (Astruc et al, 1995) as
well as in other cell lines (Gaub et al, 1990; Philips et al, 1993;
Umayahara et al, 1994; Webb et al, 1995). It is possible that as a
consequence oftransfection ofthe ER into cells that were initially
ER negative, the classical ER-mediated pathway is shifted towards
the alternate pathway.
In summary, we have shown that 4-OHT produces oestrogen-
like effects on the induction ofTGF-a gene expression in ER trans-
fectants. The observation that the TGF-ax gene is activated by both
E2 and 4-OHT in breast cancer cells is unique, as in the Ishikawa
human endometrial carcinoma cell line in which activation of
several genes by both E2 and 4-OHT is reported (Albert et al,
1990; Sundstrom et al, 1990; Jamil et al, 1991; Huynh and Pollak,
1993), TGF-x expression is up-regulated by E2 but not by 4-OHT
(Gong et al, 1992). We have, therefore, defined a novel system to
test the biochemical mechanism whereby an oestrogen- and an
antioestrogen-ER complex can induce the same gene in breast
cancer cells. The presented data suggest that there are additional
factors present in MDA-MB-231 cells that facilitate gene activa-
tion by both an oestrogen- and antioestrogen-receptor complex.
These factors may allow the antioestrogen-ER complex to be
promiscuous if the ER is overexpressed. We are in the process of
dissecting this signal transduction pathway that may suggest a
mechanism for the target site-specificity ofantioestrogens.
ABBREVIATIONS
ER, oestrogen receptor; LBD, ligand binding domain; ERE,
oestrogen response element; TGF-a, transforming growth factor
alpha; E2, 17p-oestradiol; 4-OHT, 4-hydroxytamoxifen; AP-1,
activating protein-i; CAT, chloramphenicol acetyltransferase; P2-
M, [B2-microglobulin; Tk, thymidine kinase; MMTV, mouse
mammary tumour virus; RT-PCR, reverse transcriptase-poly-
merase chain reaction; PBS, phosphate-buffered saline.
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